BranchOut Secures Approximately $750,000 in Initial Orders for New Front-of-Club Multipack Product Line and Dried Cheesecake Bites with Nation's Largest Warehouse Club Retailer

BranchOut Food's stock fell 9.3% in pre-market trading after announcing a new underwritten public offering of common stock, with Lake Street Capital Markets as the representative. The company will sell all shares, leading to equity dilution for existing shareholders. The stock had dropped 17% in after-hours trading. BranchOut Food has persistent cash burn and negative operating margins, relying on external capital raises. The broader market is up, but BranchOut Food is underperforming.

BranchOut Food Inc. (BOF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BranchOut Food Shareholder Update: Record Q2 Revenue and Major Retail Wins Position Company for Transformational Q4 and Beyond Record customer wins, rapidly increasing factory utilization, and expanding recurring business create a clear path toward significantly high

BranchOut Food Inc. (NASDAQ: BOF) reported record Q2 revenue of about $4.5 million. The company said a major warehouse club will move Crunchy Fruit Chips to an ~$8 million annual everyday program across 309 clubs starting September, plus an estimated $2 million Tropical Mix order. It expects Q4 revenue of about $6-7 million and production rising to 70-80 metric tons per month.

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

SystImmune and Bristol Myers Squibb (BMY) reported a 59% reduction in disease progression risk for iza-bren vs. chemotherapy in HR+/HER2- breast cancer. Trial showed 8.2m vs. 4.0m median PFS. BMY collaborates on iza-bren development outside China.

BioLineRx (BLRX) and Hemispherian presented preclinical data at ESMO 2026, showing GLIX1's synergy with PARP inhibitors in HR-proficient ovarian cancer models. The combination demonstrated significant tumor growth inhibition. GLIX1 is in a Phase 1/2a trial for glioblastoma, with plans to add an ovarian cancer arm. According to the companies, the data suggest GLIX1 could expand PARP inhibitors' activity to HR-proficient tumors.